Articles

Poll

Podcasts

Slideshows

Videos

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

HCPLive 5 Stories in Under 5: Week of 10/05

The therapy was well-tolerated in the phase 2a ENV-IPF-101 trial, with mostly mild-to-moderate TEAEs related to treatment.

Taladegib Shows Potential to Improve FVC in Idiopathic Pulmonary Fibrosis

The new therapy, marketed as Jascayd, previously demonstrated safety and efficacy in the phase 3 FIBRONEER-IPF trial.

Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 Years

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.



HCPLive 5 Stories in Under 5: Week of 07/13

Endeavor BioMedicines' Taladegib gains orphan drug status for idiopathic pulmonary fibrosis, showing promise in improving lung function and patient outcomes.

FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment

Yale researchers developed an AI model that illuminates critical details about—and possible treatments for—idiopathic pulmonary fibrosis. It could do so for many other diseases.

AI Helps Researchers Understand Lung Disease and Proposes Treatment

Discover the latest advancements in pulmonology, including innovative treatments for asthma, COPD, and pulmonary sarcoidosis, showcased at ATS 2025.